Determining brain age using machine learning

Determining Brain Age Using Machine Learning Combined With Automated Brain Segmentation and PET imaging In Normal, Alzheimer’s Disease and Mild Cognitive Impairment Subjects

Cortechs.ai’s  abstract titled “Determining Brain Age Using Machine Learning Combined With Automated Brain Segmentation and PET imaging In Normal, Alzheimer’s Disease and Mild Cognitive Impairment Subjects” was accepted by the Radiological Society of North America.

Lead author and Cortechs.ai Principal Scientist, Weidong Luo, will present his findings at the AI Community Learning Center, Station #1 on December 5, from 12:15 – 12:45 pm.

In addition to two other presentations throughout the conference, you can find the CorTechs team at booth numbers 4055 in South Hall, Level 3 and 10514F in the AI Showcase, Level 2.

Findings

PURPOSE
Understanding brain aging may be critical to identify potential biomarkers in neurodegenerative diseases. Here we developed a machine learning based age-prediction model for metabolic and volumetric changes of normal brain structures and evaluated this model on imaging data from patients with Alzheimer’s disease (AD) and mild cognitive impairment (MCI), as well as normal subjects.
METHOD AND MATERIALS
F18-FDG PET scans and paired T1 weighted MRI brain scans for normal subjects (59-96yo, 157m/169f), MCI (56-93yo, 263m/163f) and AD (56-91yo, 121m/80f) from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) imaging studies were used. All imaging data were processed by an automated brain PET activity analysis and MRI volumetric segmentation tool, PETQuant. The volumetric measurements, as well as the mean SUVR (Standardized uptake value (SUV) ratio) to the brain stem for all brain structures, were calculated. A subset of the normal test data (n=50) was reserved for testing. A brain aging model was created using a Random Forest machine learning algorithm with the normal subjects’ data. MCI and AD data were evaluated using this normal brain aging model.
RESULTS
We found the best age prediction was achieved by combining both PET and MRI measurements. For normal subjects, this model showed a high accuracy with the mean difference of -0.23 ± 3.1 years between actual and predicted age by model. In comparison, the MCI group had a mean difference of -2.12 ± 5.13 years, while the AD group had a mean difference of -3.59 ± 5.76 years. The AD subjects younger than 75 years old had the largest disparity between the actual and predicted ages. The predicted age based on PET/MRI measurements was on average 9.35 ± 4.52 year older than the actual age, while AD patients 75 years and above only showed a mean difference of -0.3 ± 3.26 years.
CONCLUSION
Our brain aging model showed a significant predicted age difference between normal and younger (<75yo) AD subjects. This suggests that accelerated brain aging could serve as an early biomarker for Alzheimer’s disease. This might help clinicians to identify younger subjects with AD and monitor their disease progression rates.
CLINICAL RELEVANCE/APPLICATION
Early diagnosis of Alzheimer’s disease and monitoring disease progression to improve patient management.

Authors: W Luo, PhD, San Diego, CA; A M Ulug, PhD; W Thompson, PhD; R Haxton; S Magda, PhD; L J Kjonigsen, MSc; et al. (wluo@cortechs.ai)

 

 

More Resources

08/19/2026

Brain Metastases Imaging Insights from SNO/ASCO 2026

Explore key insights from SNO/ASCO 2026 on brain metastases imaging, including lesion tracking, volumetric analysis, SRS workflows, and automated segmentation.

08/18/2026

Cortechs.ai Announces FDA Clearance for NeuroQuant® PET: Advancing Molecular Imaging for Cognitive Impairment

NeuroQuant® PET receives FDA 510(k) clearance, advancing quantitative PET imaging for cognitive impairment.

08/04/2026

Cortechs.ai Expands European CE Marking Across AI Imaging Platform, Accelerating Global Growth

Cortechs.ai expands EU CE Marking for the latest NeuroQuant®, NeuroQuant® Brain Tumor, and OnQ™ Prostate, advancing global AI imaging innovation

07/29/2026

Read Your Segmentations in the Same Space You Read the Study: Native Space Outputs in NeuroQuant v5.3.0

Review lesion segmentations directly on your original MRI images with NeuroQuant® v5.3.0.

07/23/2026

What AAIC 2026 Told Us About the Future of Dementia Imaging — And Where NeuroQuant Fits

Quantitative MRI brain volumetry with NeuroQuant.

07/09/2026

Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration

Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai’s health system network
Scroll to Top